# Patent Watch: Nutramax Targets Cannabis Combinatio

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-nutramax-targets-cannabis-combin-2026-10-06/
> **Published:** 2026-10-06T11:43:38-04:00 | **Last Modified / Clinically Audited:** 2026-10-06T11:52:06-04:00
> **Clinical Summary:** The application appears to cover formulations combining cannabis-derived material with one or more additional pharmacologically active components, with inf

---

PATENT WATCH
 US20260207634A1
 
 

# Patent Watch: Nutramax Targets Cannabis Combination Formulations

 
 **Assignee:** NUTRAMAX LABORATORIES, INC.
 **Inventors:** David Griffin
 **Published:** 2026-07-23
 
 

 
 Invention Summary & Claims
 

The application appears to cover formulations combining cannabis-derived material with one or more additional pharmacologically active components, with inflammation identified as a therapeutic focus. The published classification data suggest a combination-product strategy, but do not clearly establish a novel administration route or demonstrated bioavailability advantage.

 

 

## Clinical Perspective & Therapeutic Significance

 

Such formulations could potentially provide complementary anti-inflammatory effects or reduce reliance on higher doses of individual active ingredients. Patients and clinicians should not assume improved absorption, safety, or symptom control until the specific APIs, excipients, pharmacokinetics, dosing, and controlled clinical outcomes are reported.

 

## Intellectual Property & Market Landscape

 

Nutramax Laboratories is known for nutraceutical and joint-health products, including products positioned for human and veterinary use, making cannabinoid-based inflammation support a plausible portfolio extension. Compared with standard oils, gummies, and capsules, defensible value would depend on a specific co-formulation, reproducible manufacturing, and evidence that the combination performs better than conventional [cannabis products](https://cedclinic.com/cbd-gummies-daily-use-evidence-men/).

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260207634A1)](https://patents.google.com/patent/US20260207634A1/en).
 

 
 Editorial Commentary
 

The filing reflects continued commercial interest in positioning cannabis within structured anti-inflammatory combination products. Its practical importance will depend on claim scope, product development, regulatory strategy, and credible clinical validation.

 

 
 

### Frequently Asked Questions

 
 Could this formulation provide better anti-inflammatory relief than standard CBD products?
 Possibly, but a patent application alone does not demonstrate superior relief. Comparative pharmacokinetic and controlled clinical studies would be needed to confirm meaningful advantages.

 Does publication of this patent mean the formulation has passed clinical trials?
 No. Patent publication concerns intellectual property claims and does not establish FDA approval, clinical efficacy, or safety.

 When might products based on this application become available?
 No reliable timeline can be determined from the application alone. Availability would depend on patent prosecution, formulation development, manufacturing, regulatory requirements, and the intended human or veterinary market.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).